Physician profile
Michael A Snyder
NPI 1649519869
$5,183.79
in general payments reported to CMS, 2019-2025
36 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $1,223 · 2023: $950 · 2024: $1,340 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.42 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $700.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $685.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $627.31 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $470.48 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $178.14 | 2023-2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $148.07 | 2022-2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.99 | 2021-2025 | Xifaxan |
| Eisai INC. | $98.44 | 2024 | |
| Exact Sciences Corporation | $91.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Intuitive Surgical, INC. | $82.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $80.35 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $48.28 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $44.22 | 2023-2024 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.87 | 2022-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $35.24 | 2024 | Veozah |
| Amgen INC. | $34.70 | 2022-2025 | Evenity |
| Sunovion Pharmaceuticals INC. | $34.14 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.25 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $27.02 | 2024-2025 | Heplisav-B |
| C. R. Bard, INC. & Subsidiaries | $25.49 | 2024 | |
| Lundbeck LLC | $23.31 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $21.75 | 2025 | Inspire |
| Avanir Pharmaceuticals, INC. | $21.69 | 2022 | |
| Axsome Therapeutics, INC. | $20.09 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $19.75 | 2025 | Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $19.59 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2022 | |
| Philips North America LLC | $18.23 | 2023 | |
| Irhythm Technologies, INC. | $16.84 | 2024 | Zio Monitor, Zio Xt Patch |
| Corcept Therapeutics | $15.70 | 2025 | Korlym |
| Corium, LLC | $14.96 | 2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $14.07 | 2022 | |
| Seqirus USA INC | $12.67 | 2021 | |
| Sumitomo Pharma America, INC. | $10.03 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.